FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020387003> ?p ?o ?g. }

• W2020387003 endingPage "383" @default.
• W2020387003 startingPage "373" @default.
• W2020387003 abstract "The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly target this pathway with mTOR inhibitors have had limited success. We present the results of a preclinical study of the selective alpha/delta isoform dominant PI3K inhibitor BAY 80-6946 tested alone and in combination with HER2-targeted therapies in HER2-positive cell lines, including models with acquired resistance to trastuzumab and/or lapatinib. A panel of HER2-positive breast cancer cells were profiled for their mutational status using Sequenom MassARRAY, PTEN status by Western blot, and anti-proliferative response to BAY 80-6946 alone and in combination with the HER2-targeted therapies trastuzumab, lapatinib and afatinib. Reverse phase protein array was used to determine the effect of BAY 80-6946 on expression and phosphorylation of 68 proteins including members of the PI3K and MAPK pathways. The Boyden chamber method was used to determine if BAY 80-6946 affected cellular invasion and migration. BAY 80-6946 has anti-proliferative and anti-invasive effects when used alone in our panel of cell lines (IC50s 3.9-29.4 nM). BAY 80-6946 inhibited PI3K signalling and was effective in cells regardless of their PI3K, P53 or PTEN status. The combination of HER2-targeted therapies and BAY 80-6946 inhibited growth more effectively than either therapy used alone (with clear synergism in many cases), and can restore sensitivity to trastuzumab and lapatinib in cells with acquired resistance to either trastuzumab and/or lapatinib. The addition of BAY 80-6946 to HER2-targeted therapy could represent an improved treatment strategy for patients with refractory metastatic HER2-positive breast cancer, and should be considered for clinical trial evaluation." @default.
• W2020387003 created "2016-06-24" @default.
• W2020387003 creator A5011649305 @default.
• W2020387003 creator A5032546540 @default.
• W2020387003 creator A5046521768 @default.
• W2020387003 creator A5053110781 @default.
• W2020387003 creator A5066488338 @default.
• W2020387003 creator A5074566433 @default.
• W2020387003 creator A5081941904 @default.
• W2020387003 creator A5090856144 @default.
• W2020387003 date "2014-12-21" @default.
• W2020387003 modified "2023-10-18" @default.
• W2020387003 title "A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib" @default.
• W2020387003 cites W1981406217 @default.
• W2020387003 cites W1997579117 @default.
• W2020387003 cites W2000241906 @default.
• W2020387003 cites W2010601523 @default.
• W2020387003 cites W2015512041 @default.
• W2020387003 cites W2020372547 @default.
• W2020387003 cites W2029281176 @default.
• W2020387003 cites W2033795441 @default.
• W2020387003 cites W2046584993 @default.
• W2020387003 cites W2087005086 @default.
• W2020387003 cites W2087861588 @default.
• W2020387003 cites W2093098485 @default.
• W2020387003 cites W2102148658 @default.
• W2020387003 cites W2103786597 @default.
• W2020387003 cites W2104289405 @default.
• W2020387003 cites W2106036365 @default.
• W2020387003 cites W2106715939 @default.
• W2020387003 cites W2108070374 @default.
• W2020387003 cites W2109439031 @default.
• W2020387003 cites W2112001957 @default.
• W2020387003 cites W2127339720 @default.
• W2020387003 cites W2141393790 @default.
• W2020387003 cites W2149908785 @default.
• W2020387003 cites W2152654745 @default.
• W2020387003 cites W2169450835 @default.
• W2020387003 cites W2331534532 @default.
• W2020387003 cites W2340751767 @default.
• W2020387003 cites W3011736856 @default.
• W2020387003 doi "https://doi.org/10.1007/s10549-014-3239-5" @default.
• W2020387003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25528022" @default.
• W2020387003 hasPublicationYear "2014" @default.
• W2020387003 type Work @default.
• W2020387003 sameAs 2020387003 @default.
• W2020387003 citedByCount "39" @default.
• W2020387003 countsByYear W20203870032015 @default.
• W2020387003 countsByYear W20203870032016 @default.
• W2020387003 countsByYear W20203870032017 @default.
• W2020387003 countsByYear W20203870032018 @default.
• W2020387003 countsByYear W20203870032019 @default.
• W2020387003 countsByYear W20203870032020 @default.
• W2020387003 countsByYear W20203870032021 @default.
• W2020387003 countsByYear W20203870032022 @default.
• W2020387003 countsByYear W20203870032023 @default.
• W2020387003 crossrefType "journal-article" @default.
• W2020387003 hasAuthorship W2020387003A5011649305 @default.
• W2020387003 hasAuthorship W2020387003A5032546540 @default.
• W2020387003 hasAuthorship W2020387003A5046521768 @default.
• W2020387003 hasAuthorship W2020387003A5053110781 @default.
• W2020387003 hasAuthorship W2020387003A5066488338 @default.
• W2020387003 hasAuthorship W2020387003A5074566433 @default.
• W2020387003 hasAuthorship W2020387003A5081941904 @default.
• W2020387003 hasAuthorship W2020387003A5090856144 @default.
• W2020387003 hasBestOaLocation W20203870032 @default.
• W2020387003 hasConcept C121608353 @default.
• W2020387003 hasConcept C126322002 @default.
• W2020387003 hasConcept C143998085 @default.
• W2020387003 hasConcept C2777329042 @default.
• W2020387003 hasConcept C2777609662 @default.
• W2020387003 hasConcept C2779786085 @default.
• W2020387003 hasConcept C2781230642 @default.
• W2020387003 hasConcept C502942594 @default.
• W2020387003 hasConcept C530470458 @default.
• W2020387003 hasConcept C55493867 @default.
• W2020387003 hasConcept C62478195 @default.
• W2020387003 hasConcept C71924100 @default.
• W2020387003 hasConcept C86554907 @default.
• W2020387003 hasConcept C86803240 @default.
• W2020387003 hasConcept C98274493 @default.
• W2020387003 hasConceptScore W2020387003C121608353 @default.
• W2020387003 hasConceptScore W2020387003C126322002 @default.
• W2020387003 hasConceptScore W2020387003C143998085 @default.
• W2020387003 hasConceptScore W2020387003C2777329042 @default.
• W2020387003 hasConceptScore W2020387003C2777609662 @default.
• W2020387003 hasConceptScore W2020387003C2779786085 @default.
• W2020387003 hasConceptScore W2020387003C2781230642 @default.
• W2020387003 hasConceptScore W2020387003C502942594 @default.
• W2020387003 hasConceptScore W2020387003C530470458 @default.
• W2020387003 hasConceptScore W2020387003C55493867 @default.
• W2020387003 hasConceptScore W2020387003C62478195 @default.
• W2020387003 hasConceptScore W2020387003C71924100 @default.
• W2020387003 hasConceptScore W2020387003C86554907 @default.
• W2020387003 hasConceptScore W2020387003C86803240 @default.
• W2020387003 hasConceptScore W2020387003C98274493 @default.
• W2020387003 hasIssue "2" @default.
• W2020387003 hasLocation W20203870031 @default.

• next